Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.0K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

807
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
807
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Translational insights into extracellular vesicles in peritoneal dialysis.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis·2026
Same author

A Mathematical Model of Cysteine-Driven Metabolic Adaptation to Hypoxia in Ovarian Cancer.

Bioengineering (Basel, Switzerland)·2026
Same author

Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity.

FEBS open bio·2026
Same author

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting.

Molecules (Basel, Switzerland)·2025
Same author

Correction: Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM).

Cancer gene therapy·2025
Same author

Lactate-coated polyurea-siRNA dendriplex: a gene therapy-directed and metabolism-based strategy to impair glioblastoma (GBM).

Cancer gene therapy·2025

Related Experiment Video

Updated: Nov 7, 2025

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.3K

Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.

Filipa Lopes-Coelho1,2, Filipa Martins1,2, Sofia A Pereira2

  • 1Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal.

International Journal of Molecular Sciences
|April 30, 2021
PubMed
Summary

Revisiting older anti-angiogenic drugs targeting tumor microenvironment mechanisms may improve cancer treatment. Combining therapies that target alternative pathways shows promise for overcoming current limitations.

Keywords:
VEGFanti-angiogenic therapycancer therapydrug resistanceneo-angiogenesisnew targets

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K
Author Spotlight: Investigating Angiogenesis Through Challenges and Innovations in Assay Development
09:16

Author Spotlight: Investigating Angiogenesis Through Challenges and Innovations in Assay Development

Published on: May 31, 2024

1.6K

Related Experiment Videos

Last Updated: Nov 7, 2025

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

1.3K
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K
Author Spotlight: Investigating Angiogenesis Through Challenges and Innovations in Assay Development
09:16

Author Spotlight: Investigating Angiogenesis Through Challenges and Innovations in Assay Development

Published on: May 31, 2024

1.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Anti-angiogenic therapy aims to starve tumors by inhibiting blood vessel formation.
  • Current therapies often target vascular endothelial growth factor (VEGF), a key driver of angiogenesis.
  • VEGF also plays a role in immune suppression within the tumor microenvironment.

Purpose of the Study:

  • To review molecular mechanisms of anti-angiogenic strategies and their limitations.
  • To explore alternative mechanisms impacting angiogenesis.
  • To propose novel therapeutic strategies for cancer treatment.

Main Methods:

  • Literature review focusing on molecular mechanisms of angiogenesis.
  • Analysis of factors contributing to anti-angiogenic therapy failure.
  • Investigation of alternative pathways influencing tumor vascularization.

Main Results:

  • VEGF-targeted therapies are insufficient in many cancer cases.
  • The tumor microenvironment harbors alternative angiogenesis regulators.
  • Rehabilitating older drugs targeting these alternative mechanisms is a potential strategy.

Conclusions:

  • Combinatorial targeting of alternative angiogenic pathways offers a promising solution.
  • Repurposing existing drugs may enhance anti-angiogenic efficacy.
  • Future research should focus on multifaceted therapeutic approaches for cancer.